Rights to sell potential new medicine for HAE in Canada granted to Montreal-based company 

The company which has developed sebetralstat, a potential new oral treatment for HAE, has granted Pendopharm the exclusive rights to manage the Canadian regulatory approval process and commercialization of the medicine.

Ben Palleiko, CEO of KalVista, said: “We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE. This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care.”

(Source: KalVista)